Articles · Retatrutide
3 retatrutide mistakes I see beginners make
Retatrutide ("retta") is the compound everyone in my comments asks about. It's a single molecule that activates three receptors at once: GIP, GLP-1 and glucagon. In the phase 2 obesity trial published in the New England Journal of Medicine, participants on the highest dose lost an average of about 24% of their body weight at 48 weeks.[1] No previous obesity medication had posted a number like that in a trial of that length.
Results like that bring a lot of beginners, and I keep seeing the same three mistakes, plus a fourth that ends people's progress early. Important context first: retatrutide is still investigational. It's in phase 3 trials and is not FDA-approved, so anyone using it should be working with a clinician.
Mistake 1: Starting too high
More is not better. Patience wins with retta. Look at how the trials were designed: participants didn't start at their target dose. They escalated step by step over weeks, and in the obesity trial the arm that started lower had fewer gastrointestinal side effects than the arm that started higher.[1] The most common side effects across retatrutide trials were nausea, diarrhea, vomiting and constipation, and they were dose-related and mostly mild to moderate.[1][2]
The people who rush the climb are the people who end up miserable and quitting. Slow escalation is the protocol, not a weakness.
Mistake 2: Ignoring protein
Appetite drops. Your muscle doesn't have to. When you lose weight fast, part of what you lose is lean mass. A 2024 review of GLP-1-based therapies in Diabetes, Obesity and Metabolism found lean mass typically makes up a meaningful share of total weight lost, and it points to adequate protein and resistance training as the main ways to protect it.[3]
This isn't new science. A 2016 meta-analysis in older adults found that higher-protein diets during weight loss preserved more lean mass than lower-protein diets.[4] When you're barely hungry, protein is the first thing that falls off the plate. Plan it: protein first at every meal, and lift.
Mistake 3: No plan for plateaus
Stalls happen. Have a next step ready. Even in the trial data, weight loss curves are steep early and then flatten as the body adapts.[1] A plateau isn't failure. It's physiology. The people who do well have already decided, with their clinician, what they'll adjust: training, protein, sleep, total food quality, or the protocol itself. The people who panic make random changes and lose momentum.
Bonus mistake: Quitting at the first side effects
Most early issues pass. Nausea and GI symptoms in these trials were concentrated in the escalation period and tended to ease as people stayed on a stable dose.[1][2] That doesn't mean you push through anything. It means you talk to your clinician before you quit, because the fix is often slowing the escalation, not abandoning the plan.
Why the triple mechanism matters
Retatrutide is different from the GLP-1 drugs most people know. Adding glucagon receptor activity on top of GIP and GLP-1 is thought to increase energy expenditure and liver fat burning, not just reduce appetite. That's part of why the weight loss numbers in phase 2 were so large, and it's also why the type 2 diabetes trial in The Lancet showed strong improvements in blood sugar alongside weight loss.[2] A more powerful compound makes the basics more important, not less. The faster the weight comes off, the more protein, training and patience decide how much of it is fat versus muscle.
The takeaway
Retatrutide has some of the most impressive trial data in the weight loss space, but results come from doing it right: slow escalation, protein and training to protect muscle, a plan for plateaus, and medical supervision throughout. Save this before you start.
If you want a structured plan built around your goals, that's what The Peptide Lab coaching is for.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PubMed 37366315
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023. PubMed 37385280
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. PubMed 38937282
- Kim JE, et al. Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis. Nutr Rev. 2016. PubMed 26883880